购物车
- 全部删除
- 您的购物车当前为空
YGT-31作为PPARγ调节剂,其IC50值为1.72 μM,Ki值为0.62 μM.通过抑制CDK5介导的PPARγ-Ser273的磷酸化,YGT-31能在db/db小鼠的2型糖尿病模型中显著降低血糖并改善胰岛素抵抗.此外,YGT-31在小鼠的非酒精性脂肪性肝病(NAFLD)模型中也展示了抗肝脂肪变性的效果.
YGT-31作为PPARγ调节剂,其IC50值为1.72 μM,Ki值为0.62 μM.通过抑制CDK5介导的PPARγ-Ser273的磷酸化,YGT-31能在db/db小鼠的2型糖尿病模型中显著降低血糖并改善胰岛素抵抗.此外,YGT-31在小鼠的非酒精性脂肪性肝病(NAFLD)模型中也展示了抗肝脂肪变性的效果.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | YGT-31 is a PPARγ modulator with an IC50 of 1.72 μM and a Ki of 0.62 μM. It diminishes blood glucose levels and enhances insulin sensitivity in a type 2 diabetes model in db/db mice by inhibiting CDK5-mediated phosphorylation of PPARγ-Ser273. Additionally, YGT-31 exhibits anti-steatotic effects in a mouse model of non-alcoholic fatty liver disease (NAFLD). |
靶点活性 | PPARγ:0.62 μM (Ki), PPARγ:1.72 μM |
分子量 | 469.41 |
分子式 | C25H18F3NO5 |
CAS No. | 2835447-74-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容